Now showing items 11-20 of 1118
Age at Diagnosis and Quality of Life in Breast Cancer Survivors
(Blackwell Publishing, Inc., 2002-03)
The purpose of the study was to determine the relationship between life-stage variables (ie, age at diagnosis and years of survival) and quality-of-life (QOL) outcomes in long-term survivors of breast cancer. description ...
Hemostasis management and therapeutic plasma exchange: Results of a practice survey
(John Wiley & Sons, Inc., 2018-10)
BackgroundPatients undergoing therapeutic plasma exchange (TPE) may present with risks for hemorrhage or thrombosis. Use of replacement fluids devoid of coagulation factors will decrease factor levels and platelet levels. ...
Expedition Inspiration Fund for Breast Cancer Research Meeting 2003
(Kluwer Academic Publishers; Springer Science+Business Media, 2003-07)
How does interferon work? Does it even matter? See referenced original article on pages 1101–12, this issue.
(Wiley Subscription Services, Inc., A Wiley Company, 2002-09-01)
No abstract.
A comparative prospective observational study of children and adults with immune thrombocytopenia: 2‐year follow‐up
(Lippincott Williams & WilkinsWiley Periodicals, Inc., 2018-06)
Comparative clinical studies of children and adults with immune thrombocytopenia (ITP) are poorly covered in the literature. However, the accepted classification of ITP—childhood ITP and adult ITP—results in considerable ...
Prostate carcinoma presentation, diagnosis, and staging
(Wiley Subscription Services, Inc., A Wiley Company, 2003-09-15)
BACKGROUND Based on the 1998 Patient Care Evaluation (PCE) from the American College of Surgeons National Cancer Data Base (NCDB), the authors described contemporary nationwide patterns of prostate carcinoma presentation, ...
Impact of sarcopenia on treatment tolerance in United States veterans with diffuse large B‐cell lymphoma treated with CHOP‐based chemotherapy
(Wiley Periodicals, Inc.IARC Press, 2016-10)
The Search for Occult Metastatic Disease in Breast Cancer Patients: How Far Should We Go?
(Springer-Verlag; The Society of Surgical Oncology, Inc., 2006-05)
Artificial neural networks for prostate carcinoma risk assessment
(John Wiley & Sons, Inc., 2001-04-15)
No abstract.